Island Pharmaceuticals Limited (ILA.AX)

0,0560 0,0000 (0,00%) Börsenschluss: 03:50PM AEST

Island Pharmaceuticals Limited

697 Burke Road
Suite 201
Camberwell, VIC 3124
Australia
61 3 7036 7675
https://www.islandpharmaceuticals.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Paul Donald Richard MacLeman BVSc, D.V.M., F.A.C.I.D., GAICD, Grad Cert Eng, Gr	Executive Chairman	164,92k	N/A	1966
Dr. David Charles Foster J.D., M.A.I.C.D., Ph.D.	MD, CEO, President & Executive Director	306,7k	N/A	N/A
Mr. Cameron Jones C.A.	Joint Company Secretary	N/A	N/A	N/A
Stephanie Vipond	Joint Company Secretary	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in AUD.

Beschreibung

Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; and research collaboration agreement with Compounds Australia, a drug library containing various molecules that could be searched for drug re-purposing and pipeline development. It also has a cooperative research and development agreement with the U.S. Army in preparation for its Phase II clinical study for ISLA-101; supply agreement with Catalent for manufacture of Fenretinide softgels for dengue fever trial participants; and right to reference National Cancer Institute IND for Isla101. The company was incorporated in 2020 and is based in Camberwell, Australia.

Corporate Governance

Island Pharmaceuticals Limiteds ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.